VCA Stocks

The Swedish pharmaceutical company Moberg Derma AB, which focuses on skin diseases, has completed a new issue generating SEK 40 million ($6.5 million).  Moberg Derma develops dermatological pharmaceuticals to treat common skin diseases. The company has two products in phase III clinical trials - K101 which is a topical treatment for nail fungus and K301 which is a cortisone-free treatment for seborrheic dermatitis of the scalp.